VK2735

Viking Therapeutics

VK2735 is an experimental dual agonist that activates both the GIP and GLP-1 receptors — the same two-pathway strategy behind the approved drug tirzepatide. By engaging GLP-1 to reduce appetite and improve glucose handling, and GIP to complement those metabolic effects, dual agonists aim for greater weight loss than GLP-1 agonism alone. Viking Therapeutics is developing VK2735 as a next-generation entrant in this crowded and fast-moving obesity-drug space. What has made VK2735 notable is that Viking is advancing it in two formats: a subcutaneous injectable and an oral tablet. Early-phase clinical studies of the subcutaneous form reported meaningful mean weight reductions over a few months, and a separate oral program has reported encouraging early results — an important storyline because orally available incretin drugs could broaden access beyond injections. As with all early data, these are small, short studies whose findings are promising signals rather than confirmed efficacy. VK2735 is investigational and not approved anywhere. It requires larger and longer phase 2 and phase 3 trials to establish how much weight loss it produces durably, how well it is tolerated during dose titration (gastrointestinal side effects are the expected class issue), and its long-term safety. It is included here as an educational reference on an emerging metabolic drug, not as a product available for legitimate purchase or self-administration — grey-market 'VK2735' should be regarded as unverified and unsafe.